X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Part B 101: Three charts show the program helps control costs for health care system and enrollees

By Nicole Longo  |    February 18, 2022
Medicare Part B covers a wide range of health care services, including physician office visits, hospital outpatient care and medical equipment. It also covers medicines that are usually administered...   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...   Read More

Making medicines more affordable: Modernizing Medicare

By Emilie Signora  |    November 11, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

By Gabby Migliara  |    October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...   Read More

Recent polling misrepresents public support for Medicare “negotiation”

By Tom Wilbur  |    August 31, 2021
Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy firms...   Read More

What they’re saying: Patient advocates want to protect Medicare from government interference

By Gabby Migliara  |    August 24, 2021
For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise of...   Read More

The ABCs (and Ds) of Medicare

By Gabby Migliara  |    May 13, 2021
For nearly 60 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. Medicare has many different programs, all...   Read More

New analysis finds stark difference in coverage of breast cancer medicines for seniors in the United States and England

By Nicole Longo  |    December 10, 2020
In the United States, seniors and people with disabilities enjoy broad coverage of physician-administered medicines under Medicare Part B because the program relies on market competition to balance...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates